Loading organizations...
§ Private Profile · 81 Rue du Pre Catelan, Paris, France
Medical device company developing wearable cardioverter defibrillators and digital healthcare solutions for at-risk cardiac patients.
Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions for cardiac patients, including the ASSURE® system, and is based in Kirkland, Washington. The company's core focus is on providing advanced diagnostic monitoring and therapeutic technologies specifically designed for at-risk cardiovascular patients. Kestra operates as a commercial-stage company, generating revenue primarily through the sales of its medical devices and associated services. The ASSURE® system itself comprises a wearable cardioverter defibrillator, a patient application, and a remote monitoring platform, offering a comprehensive solution for patient care. Kestra is a privately held entity, with Bain Capital Life Sciences identified as its primary known investor. The organization was founded in 2014 by a team of experienced leaders from the automated external defibrillator (AED) and implantable cardioverter defibrillator (ICD) industries.
Kestra Technologies has raised $11.0M across 2 funding rounds.
Kestra Technologies has raised $11.0M in total across 2 funding rounds.
Kestra Technologies has raised $11.0M in total across 2 funding rounds.
Kestra Technologies's investors include Alven, F3A, OpenCapital.vc, Y Combinator.
Kestra Technologies has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M Seed in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $8M Seed | Alven | F3A, Opencapital.vc, Y Combinator | Announced |
| Oct 1, 2023 | $3M Seed | — | Alven, F3A, Opencapital.vc, Y Combinator | Announced |
Kestra Medical Technologies is a commercial-stage wearable medical device and digital healthcare company that develops intuitive, intelligent, and connected technologies to protect cardiac patients at risk of sudden cardiac arrest (SCA).[1][2][3][4] Its flagship ASSURE Cardiac Recovery System integrates the ASSURE WCD (wearable cardioverter defibrillator), a patient app, and the Kestra CareStation remote data platform to enable monitoring, autonomous detection, defibrillation therapy, and patient-provider collaboration, addressing a leading cause of death that claims 475,000 lives annually in the US.[1][3][4] The company serves at-risk cardiac patients and healthcare providers, solving the problem of temporary protection during high-risk recovery periods when implantable devices may not yet be indicated, with strong commercial momentum evidenced by real-world studies like the ACE-PAS trial and listings on NASDAQ (ticker: KMTS).[3][4]
Backed by Bain Capital Life Sciences, Kestra focuses on cardiovascular outcomes through innovation in Class III medical devices, emphasizing patient compliance, comfort, and provider clarity.[1][2]
Kestra Medical Technologies was founded in 2014 in Kirkland, Washington, by leaders from the automated external defibrillator (AED) and implantable cardioverter defibrillator (ICD) industries, driven by the vision to create modern, wearable diagnostic and therapeutic products.[1][2] This expertise in defibrillation technologies inspired the development of next-generation wearables to bridge gaps in SCA risk management. Key leaders include Brian Webster, President and CEO, and Traci Umberger, Chief Administrative Officer and General Counsel, supported by a team with deep Class III device experience.[1]
Early traction came from launching the ASSURE system, which gained commercial validation through studies like ACE-PAS—the largest prospective real-world evaluation of wearable defibrillators—demonstrating performance, safety, and usability.[4] As a Bain Capital portfolio company, it has scaled toward public markets with a NASDAQ listing.[2][3]
Kestra stands out in the medtech space through these key strengths:
Kestra rides the convergence of digital health, wearables, and AI-driven cardiac monitoring, capitalizing on rising SCA awareness amid aging populations and post-COVID cardiovascular risks.[1][4] Timing is ideal as remote patient management surges, with market forces like value-based care favoring connected devices that cut readmissions and enable precise interventions over traditional ICDs.[3][4] By influencing ecosystems through provider education (e.g., HRS and AHA conferences) and data platforms, Kestra advances SCA prevention, potentially reshaping guidelines for temporary high-risk protection.[1][4]
Kestra is poised for expansion with pipeline advancements in SCA management and leveraging ACE-PAS momentum for broader adoption, especially as wearable tech integrates deeper into telecardiology.[4] Trends like AI-enhanced detection and global digital health growth will accelerate its trajectory, with NASDAQ status unlocking capital for R&D and international reach.[3] Its influence may evolve to set standards in mobile therapeutics, transforming outcomes for millions at SCA risk—echoing its founding mission to protect through intuitive innovation.[1][2]